Lilly's triple agonist outperformed semaglutide on both weight and blood sugar in people with type 2 diabetes, per Medscape's report on the head-to-head data.
Recap by typeshit. Full story at Medscape.
Popular Mechanics traces how her 1980s work at Mass General showed GLP-1 triggers insulin release. Gallup now puts GLP-1 weight loss use at about 11% of Americans.
Barzilai highlights trial results on retatrutide in adults with sleep apnea and obesity or overweight, a new use being tested for Lilly's drug.
The Washington meeting runs November 14 to 17, with primary REDEFINE 9 results and pediatric semaglutide research for kids 6 to under 12.
Researchers tracked spending on drinks while out and found a sharp drop among people taking GLP-1 medications.
The Irish Mirror shares Dr Amir Khan's advice for anyone planning to come off weight loss jabs, with the full story linked from its page.
MedWatch reports a 4.2% weekly rise, the highest level for the oral weight loss pill since it launched earlier this year.
Loading…